Clementia Pharmaceuticals Inc. Announces Receipt of Final Court Approval for Plan of Arrangement With Ipsen S.A.
Clementia Pharmaceuticals Inc. Announces Receipt of Final Court Approval for Plan of Arrangement With Ipsen S.A.
April 11, 2019 at 12:00 PM EDT
MONTREAL, April 11, 2019 (GLOBE NEWSWIRE) — Clementia Pharmaceuticals Inc.(Nasdaq: CMTA) (“Clementia” or the “Corporation”) is pleased to announce that the Québec Superior Court issued earlier today a final order approving the previously announced statutory plan of arrangement under the Canada Business Corporations Act pursuant to which a wholly-owned subsidiary of Ipsen S.A. will acquire all of the issued and outstanding common shares of Clementia for US$25.00 per share in cash upfront on completion of the transaction plus a deferred payment on the achievement of a future regulatory milestone in the form of a contingent value right of US$6.00 per share payable upon the U.S. Food and Drug Administration’s (FDA) acceptance of submission of a new drug application (NDA) filing for palovarotene for the treatment of multiple osteochondromas (MO) on or prior to December 31, 2024.
Clementia Pharmaceuticals Inc. Announces Receipt of Final Court Approval for Plan of Arrangement With Ipsen S.A.
April 11, 2019 at 12:00 PM EDT
MONTREAL, April 11, 2019 (GLOBE NEWSWIRE) — Clementia Pharmaceuticals Inc.(Nasdaq: CMTA) (“Clementia” or the “Corporation”) is pleased to announce that the Québec Superior Court issued earlier today a final order approving the previously announced statutory plan of arrangement under the Canada Business Corporations Act pursuant to which a wholly-owned subsidiary of Ipsen S.A. will acquire all of the issued and outstanding common shares of Clementia for US$25.00 per share in cash upfront on completion of the transaction plus a deferred payment on the achievement of a future regulatory milestone in the form of a contingent value right of US$6.00 per share payable upon the U.S. Food and Drug Administration’s (FDA) acceptance of submission of a new drug application (NDA) filing for palovarotene for the treatment of multiple osteochondromas (MO) on or prior to December 31, 2024.
Related Press Releases
![Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
![IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2024 IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2024](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2024
![Ipsen – June 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital Ipsen – June 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
Ipsen – June 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
![Half-year statement of IPSEN liquidity agreement – 2024 06 30 Half-year statement of IPSEN liquidity agreement – 2024 06 30](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
Half-year statement of IPSEN liquidity agreement – 2024 06 30
![IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2024 IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2024](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2024
![Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
![IPSEN – Buy-back programme – Art 5 of MAR – Week 25 – 2024 IPSEN – Buy-back programme – Art 5 of MAR – Week 25 – 2024](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
IPSEN – Buy-back programme – Art 5 of MAR – Week 25 – 2024
![IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2024 IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2024](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2024
![IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2024 IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2024](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2024
![Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)